Dishman Carbogen Amcis Ltd vs Jenburkt Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Dishman Carbogen Amcis Ltd is ₹ 183.6 as of 30 Apr 15:30 . The P/E Ratio of Dishman Carbogen Amcis Ltd changed from 161 on March 2022 to 1036 on March 2025 . This represents a CAGR of 59.28% over 4 yearsThe P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 1708 crore on March 2021 to ₹ 3411 crore on March 2025 . This represents a CAGR of 14.83% over 5 yearsThe Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 726.46 crore as compare to the Sep '25 revenue of ₹ 660.76 crore. This represent the growth of 9.94% The revenue of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 119.77 crore as compare to the Sep '25 ebitda of ₹ 157 crore. This represent the decline of -23.71% The ebitda of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Dishman Carbogen Amcis Ltd changed from ₹ -77.57 crore to ₹ -12.97 crore over 7 quarters. This represents a CAGR of -64.01% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 years .

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited was formerly incorporated as 'Carbogen Amcis (India) Limited' on July 17, 2007.
The Company name later on, was changed to 'Dishman Carbogen Amcis Limited' on 27 March 2017.
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants.
It works manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.
The name of Carbogen Amcis (India) Ltd.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

FAQs for the comparison of Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd

Which company has a larger market capitalization, Dishman Carbogen Amcis Ltd or Jenburkt Pharmaceuticals Ltd?

Market cap of Dishman Carbogen Amcis Ltd is 2,878 Cr while Market cap of Jenburkt Pharmaceuticals Ltd is 460 Cr

What are the key factors driving the stock performance of Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd?

The stock performance of Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd?

As of May 4, 2026, the Dishman Carbogen Amcis Ltd stock price is INR ₹183.6. On the other hand, Jenburkt Pharmaceuticals Ltd stock price is INR ₹1044.25.

How do dividend payouts of Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dishman Carbogen Amcis Ltd and Jenburkt Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.